|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forner A, Hessheimer AJ, Isabel Real M and
Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol
Hematol. 60:89–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guglielmi A, Ruzzenente A, Conci S,
Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G and
Iacono C: Hepatocellular carcinoma: Surgical perspectives beyond
the barcelona clinic liver cancer recommendations. World J
Gastroenterol. 20:7525–7533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishizawa T, Hasegawa K, Aoki T, Takahashi
M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N and Makuuchi M:
Neither multiple tumors nor portal hypertension are surgical
contraindications for hepatocellular carcinoma. Gastroenterology.
134:1908–1916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saito M, Shiraishi K, Matsumoto K,
Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H,
Watanabe S, Tsuta K, et al: A three-microRNA signature predicts
responses to platinum-based doublet chemotherapy in patients with
lung adenocarcinoma. Clin Cancer Res. 20:4784–4793. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G,
Yang J, Xia L, Wang R, Cai X, Hu H, et al: MicroRNA-149 inhibits
proliferation and cell cycle progression through the targeting of
ZBTB2 in human gastric cancer. PLoS One. 7:e416932012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan SH, Huang WC, Chang JW, Chang KJ, Kuo
WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, et al: MicroRNA-149
targets GIT1 to suppress integrin signaling and breast cancer
metastasis. Oncogene. 33:4496–4507. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Ma YL, Zhang P, Shen TY, Shi CZ,
Yang YZ, Moyer MP, Zhang HZ, Chen HQ, Liang Y and Qin HL: SP1
mediates the link between methylation of the tumour suppressor
miR-149 and outcome in colorectal cancer. J Pathol. 229:12–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Øster B, Linnet L, Christensen LL, Thorsen
K, Ongen H, Dermitzakis ET, Sandoval J, Moran S, Esteller M, Hansen
TF, et al: Non-CpG island promoter hypomethylation and miR-149
regulate the expression of SRPX2 in colorectal cancer. Int J
Cancer. 132:2303–2315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chung GE, Yoon JH, Myung SJ, Lee JH, Lee
SH, Lee SM, Kim SJ, Hwang SY, Lee HS and Kim CY: High expression of
microRNA-15b predicts a low risk of tumor recurrence following
curative resection of hepatocellular carcinoma. Oncol Rep.
23:113–119. 2010.PubMed/NCBI
|
|
14
|
Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW,
Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al: MicroRNA-122, a
tumor suppressor microRNA that regulates intrahepatic metastasis of
hepatocellular carcinoma. Hepatology. 49:1571–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y,
Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis,
tumorigenicity, and prognosis of hepatocellular carcinoma.
Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
16
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Li J, Shen J, Wang C, Yang L and
Zhang X: MicroRNA-182 downregulates metastasis suppressor 1 and
contributes to metastasis of hepatocellular carcinoma. BMC Cancer.
12:2272012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Najafi-Shoushtari SH, Kristo F, Li Y,
Shioda T, Cohen DE, Gerszten RE and Näär AM: MicroRNA-33 and the
SREBP host genes cooperate to control cholesterol homeostasis.
Science. 328:1566–1569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuo PL, Liao SH, Hung JY, Huang MS and Hsu
YL: MicroRNA-33a functions as a bone metastasis suppressor in lung
cancer by targeting parathyroid hormone related protein. Biochim
Biophys Acta. 1830:3756–3766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thomas M, Lange-Grünweller K, Weirauch U,
Gutsch D, Aigner A, Grünweller A and Hartmann RK: The
proto-oncogene Pim-1 is a target of miR-33a. Oncogene. 31:918–928.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ibrahim AF, Weirauch U, Thomas M,
Grünweller A, Hartmann RK and Aigner A: MicroRNA replacement
therapy for miR-145 and miR-33a is efficacious in a model of colon
carcinoma. Cancer Res. 71:5214–5224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schaap-Oziemlak AM, Raymakers RA,
Bergevoet SM, Gilissen C, Jansen BJ, Adema GJ, Kögler G, Le Sage C,
Agami R, van der Reijden BA and Jansen JH: MicroRNA hsa-miR-135b
regulates mineralization in osteogenic differentiation of human
unrestricted somatic stem cells. Stem Cells Dev. 19:877–885. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma YS, Wu TM, Lv ZW, Lu GX, Cong XL, Xie
RT, Yang HQ, Chang ZY, Sun R, Chai L, et al: High expression of
miR-105-1 positively correlates with clinical prognosis of
hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget.
8:11896–11905. 2017.PubMed/NCBI
|
|
26
|
Fang Y, Fu D, Tang WQ, Cai Y, Ma D, Wang
H, Xue R, Liu T, Huang X, Dong L, et al: Ubiquitin C-terminal
hydrolase 37, a novel predictor for hepatocellular carcinoma
recurrence, promotes cell migration and invasion via interacting
and deubiquitinating PRP19. Biochim Biophys Acta. 1833:559–572.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu SD, Ma YS, Fang Y, Liu LL, Fu D and
Shen XZ: Role of the microenvironment in hepatocellular carcinoma
development and progression. Cancer Treat Rev. 38:218–225. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D
and Shen X: Regulatory T cell: A protection for tumor cells. J Cell
Mol Med. 16:425–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang Y, Mu J, Ma Y, Ma D, Fu D and Shen X:
The interaction between ubiquitin C-terminal hydrolase 37 and
glucose-regulated protein 78 in hepatocellular carcinoma. Mol Cell
Biochem. 359:59–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu LL, Fu D, Ma YS and Shen XZ: The power
and the promise of liver cancer stem cell markers. Stem Cells Dev.
20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang Y, Fu D and Shen XZ: The potential
role of ubiquitin C-terminal hydrolases in oncogenesis. Biochim
Biophys Acta. 1806:1–6. 2010.PubMed/NCBI
|
|
32
|
Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B,
Gu J, Chen HY and Sun XF: Clinicopathological significance of
microRNA-31, −143 and −145 expression in colorectal cancer. Dis
Markers. 26:27–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Zhang Y, Zhang Y, Ding J, Wu K and
Fan D: Survival prediction of gastric cancer by a seven-microRNA
signature. Gut. 59:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ji J, Shi J, Budhu A, Yu Z, Forgues M,
Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo G, Chao YL, Tang B, Li BS, Xiao YF,
Xie R, Wang SM, Wu YY, Dong H, Liu XD and Yang SM: miR-149
represses metastasis of hepatocellular carcinoma by targeting
actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jung KH, Zhang J, Zhou C, Shen H, Gagea M,
Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK and Beretta L:
Differentiation therapy for hepatocellular Carcinoma: Multifaceted
effects of miR-148a on tumor growth and phenotype and liver
fibrosis. Hepatology. 63:864–879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dávalos A, Goedeke L, Smibert P, Ramírez
CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U,
Pastor-Pareja JC, et al: miR-33a/b contribute to the regulation of
fatty acid metabolism and insulin signaling. Proc Natl Acad Sci
USA. 108:pp. 9232–9237. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ramirez CM, Goedeke L, Rotllan N, Yoon JH,
Cirera-Salinas D, Mattison JA, Suárez Y, de Cabo R, Gorospe M and
Fernández-Hernando C: MicroRNA 33 regulates glucose metabolism. Mol
Cell Biol. 33:2891–2902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rayner KJ, Esau CC, Hussain FN, McDaniel
AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X,
et al: Inhibition of miR-33a/b in non-human primates raises plasma
HDL and lowers VLDL triglycerides. Nature. 478:404–407. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qu J, Li M, An J, Zhao B, Zhong W, Gu Q,
Cao L, Yang H and Hu C: MicroRNA-33b inhibits lung adenocarcinoma
cell growth, invasion, and epithelial-mesenchymal transition by
suppressing Wnt/β-catenin/ZEB1 signaling. Int J Oncol.
47:2141–2152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou Y, Yang C, Wang K, Liu X and Liu Q:
MicroRNA-33b inhibits the proliferation and migration of
osteosarcoma cells via targeting hypoxia-inducible factor-1α. Oncol
Res. 25:397–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cirera-Salinas D, Pauta M, Allen RM,
Salerno AG, Ramírez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion
MA, Morales-Ruiz M, Suarez Y, et al: Mir-33 regulates cell
proliferation and cell cycle progression. Cell Cycle. 11:922–933.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, Zhou X, Shan B, Han J, Wang F, Fan
X, Lv Y, Chang L and Liu W: Downregulation of microRNA-33a promotes
cyclin-dependent kinase 6, cyclin D1 and PIM1 expression and
gastric cancer cell proliferation. Mol Med Rep. 12:6491–6500. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rice SJ, Lai SC, Wood LW, Helsley KR,
Runkle EA, Winslow MM and Mu D: MicroRNA-33a mediates the
regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid
transcription factor 1 (TTF-1/NKX2-1). J Biol Chem.
288:16348–16360. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu C, Zhao Y, Zhang Z, Ni Y, Li X and
Yong H: MicroRNA-33a inhibits lung cancer cell proliferation and
invasion by regulating the expression of β-catenin. Mol Med Rep.
11:3647–3651. 2015. View Article : Google Scholar : PubMed/NCBI
|
